Viral inactivation for pH-sensitive antibody formats such as multi-specific antibodies.

Bispecific antibodies Protein A affinity / capture chromatography Purification process Solvent/detergent treatment Viral clearance Viral inactivation

Journal

Journal of biotechnology
ISSN: 1873-4863
Titre abrégé: J Biotechnol
Pays: Netherlands
ID NLM: 8411927

Informations de publication

Date de publication:
20 Mar 2024
Historique:
received: 02 10 2023
revised: 19 01 2024
accepted: 18 02 2024
pubmed: 26 2 2024
medline: 26 2 2024
entrez: 25 2 2024
Statut: ppublish

Résumé

Recently developed multi-specific antibody formats enable new therapeutic concepts. Conveniently, formats with an Fc domain allow purification in well-established mAb platform processes. However, due to the structural complexity of the formats, the assembled molecules may be sensitive to extreme pH commonly used for viral inactivation. An alternative to low pH incubation for virus inactivation is the use of a mixture of tri-n-butyl phosphate (TnBP, solvent) and Polysorbate 80 (PS80, detergent). While TnBP is toxic, this combination has a long history of use in the manufacturing of human plasma-derived products that are sensitive to low or high pH incubation. Data are provided demonstrating that the solvent/detergent (S/D) treatment using TnBP and PS80 can be successfully used for pH-sensitive, multi-specific antibody formats in the clarified cell culture fluid (CCCF). A different placement of the S/D within the purification process, namely during the capture by Protein A (PA), has been evaluated. This alternative placement allows effective viral inactivation by S/D while preserving the viral reduction and viral inactivation achieved through the PA step itself, enabling the cumulation of these effects. Furthermore, the process alternative simplifies the liquid handling by reducing the added volumes of the required S/D liquids, thus reducing the amount of toxic TnBP to a minimum. Data are shown demonstrating a complete removal of TnBP and PS80 in the process.

Identifiants

pubmed: 38403131
pii: S0168-1656(24)00048-8
doi: 10.1016/j.jbiotec.2024.02.009
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

45-54

Informations de copyright

Copyright © 2024 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. All authors were employees of Ichnos Sciences during the time of this work.

Auteurs

Anaïs Duret (A)

Drug Substance Development, Ichnos Sciences, Switzerland.

Lionel Duarte (L)

Drug Substance Development, Ichnos Sciences, Switzerland.

Laure Cahuzac (L)

Drug Substance Development, Ichnos Sciences, Switzerland.

Apolline Rondepierre (A)

Drug Substance Development, Ichnos Sciences, Switzerland.

Monia Lambercier (M)

Drug Substance Development, Ichnos Sciences, Switzerland.

Romain Mette (R)

Drug Substance Development, Ichnos Sciences, Switzerland.

Achim Recktenwald (A)

Drug Substance Development, Ichnos Sciences, Switzerland.

Roberto Giovannini (R)

Process Development, Ichnos Sciences, Switzerland.

Martin Bertschinger (M)

Drug Substance Development, Ichnos Sciences, Switzerland.

Classifications MeSH